我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

代谢综合征患者心血管疾病的病理生理及治疗进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第5期
页码:
599-602
栏目:
综述
出版日期:
2014-05-25

文章信息/Info

Title:
Pathophysiology and therapeutics in cardiovascular disease of patients with metabolic syndrome: research progress
作者:
江振华; 王亚斌; 曹 丰
(第四军医大学西京医院心内科，陕西 西安 710032)
Author(s):
JIANG Zhen-hua;  WANG Ya-bin;  CAO Feng
(Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
代谢综合征; 心血管疾病; 病理生理过程; 综合治疗
Keywords:
metabolic syndrome;  cardiovascular disease;  pathophysiological process;  combined treatment
分类号:
R589
DOI:
-
文献标识码:
A
摘要:
代谢综合征(MetS)是多种代谢成分异常聚集的病理状态，是一组表现为一系列与心血管疾病(CVD)相关联的症候群，包括像向心性肥胖、高糖血症、血脂异常和高血压等等，这些特征与近年来不断增长的CVD的发病率和死亡率有着非常密切的联系。多重因素导致的代谢紊乱与CVD发生之间相互关联，其中胰岛素抵抗（IR）、氧化应激、低水平的炎症和血管功能不良被认为是最大的成因。因此，临床上多管齐下的综合治疗方案被用来治疗MetS患者，并且叮嘱患者应注意生活方式的改变，如健康的饮食、合理的锻炼。此外，改进胰岛素抵抗和葡萄糖的代谢，控制血压和调节血脂异常也能延缓或者逆转MetS患者的CVD进程。本综述旨在阐述MetS与CVD之间复杂的联系，讨论关于MetS患者心血管并发症的预防以及治疗的最佳方案，并介绍目前临床试验中最新的研究成果。
Abstract:
Metabolic syndrome (MetS) is the pathological state of abnormal accumulation of various metabolites that always manifest a series of syndromes characterized by cardiovascular risk factors including central obesity, hyperglycemia, dyslipidemia and hypertension, which are highly correlated with the growing morbidity and mortality rates for cardiovascular diseases (CVD). The correlation between these metabolic disorders and the development of CVD is identified to be complex and multifactorial in which insulin resistance (IR), oxidative stress, low-grade inflammation and vascular maladaptation are considered to be the leading causes. Hence, multifaceted comprehensive treatment scheme should be used to treat patients with MetS. Lifestyle changes such as weight control, healthy heart diet and regular exercises have been recommended as the first line measures to reduce the risks of CVD in MetS individuals. Improving insulin resistance and glucose metabolism, controlling blood pressure and adjusting dyslipidemia can also reverse or slow down the process of CVD in MetS. This review aims to elaborate the complex relationship between MetS and CVD, to discuss the optimal treatment regimens to prevent and treat cardiovascular complications in MetS patients and to introduce the updated results from newly released clinical trials.

参考文献/References

[1]Ogden CL,Carroll MD,Kit BK,et al.Prevalence of obesity and trends in body mass index among US children and adolescents,1999-2010[J].JAMA,2012,307(5):483-490.
[2]Guize L,Pannier B,Thomas F,et al.Recent advances in metabolic syndrome and cardiovascular disease[J].Arch Cardiovasc Dis,2008,101(9):577-583.
[3]Berwick ZC, Dick GM,Tune JD.Heart of the matter:coronary dysfunction in metabolic syndrome[J].J Mol Cell Cardiol,2012,52(4):848-856.
[4]Gauthier MS,Ruderman NB.Adipose tissue inflammation and insulin resistance:all obese humans are not created equal[J].Biochem J,2010,430(2):e1-e4.
[5]Reddy KJ,Singh M,Bangit JR,et al.The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease:an updated review[J].J Cardiovasc Med (Hagerstown), 2010, 11(9):633-647.
[6]Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease[J].Med Clin North Am,2011,95(5):875-892.
[7]Leroith D.Pathophysiology of the metabolic syndrome:implications for the cardiometabolic risks associated with type 2 diabetes[J].Am J Med Sci,2012,343(1):13-16.
[8]Yamagishi S.Cardiovascular disease in recent onset diabetes mellitus[J].J Cardiol,2011,57(3):257-262.
[9]Lavie CJ,Milani RV,O’keefe JH.Dyslipidemia intervention in metabolic syndrome:emphasis on improving lipids and linical event reduction[J].Am J Med Sci,2011,341(5):388-393.
[10]Raal FJ.Pathogenesis and management of the dyslipidemia of the metabolic syndrome[J].Metab Syndr Relat Disord,2009,7(2):83-88.
[11]Morales-Suarez-Varela MM,Mansego ML,Vicedo-Cabrera AM,et al.Inefficient arterial hypertension control in patients with metabolic syndrome and its link to renin-angiotensin-aldosterone system polymorphisms[J].Hypertens Res,2011,34(6):758-766.
[12]Chaudhary K,Buddineni JP,Nistala R,et al.Resistant hypertension in the high-risk metabolic patient[J].Curr Diab Rep,2011,11(1):41-46.
[13]Suehiro A,Wakabayashi I,Uchida K,et al.Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome[J].Thromb Res,2012,129(4):499-501.
[14]Mauras N,Delgiorno C,Kollman C,et al.Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children[J].J Clin Endocrinol Metab,2010,95(3):1060-1068.[15]Svendsen M,Helgeland M,Tonstad S.The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome[J].J Hum Nutr Diet,2009,22(1):55-63.
[16]Nagayama D,Shirai K.Sibutramine and its adequate usage[J].Nihon Rinsho,2011,69(Suppl 1):678-682.
[17]Woodward M,Patel A,Zoungas S,et al.Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial[J].Diabetes Care,2011,34(12):2491-2495.
[18]Schernthaner G.Diabetes and Cardiovascular Disease:Is intensive glucose control beneficial or deadly? Lessons from ACCORD,ADVANCE,VADT,UKPDS,PROactive,and NICE-SUGAR[J].Wien Med Wochenschr,2010,160(1-2):8-19.
[19]Muhlhauser I.Follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2009,360(4):417;author reply 418.
[20]Erdmann E,Wilcox RG.Weighing up the cardiovascular benefits of thiazolidinedione therapy:the impact of increased risk of heart failure[J].Eur Heart J,2008,29(1):12-20.
[21]Swislocki AL,Siegel D,Jialal I.Pharmacotherapy for the metabolic syndrome[J].Curr Vasc Pharmacol,2012,10(2):187-205.
[22]Nakajima K.Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome[J].Curr Clin Pharmacol,2010,5(2):133-139.
[23]Einhorn PT,Davis BR,Wright JT,et al.ALLHAT:still providing correct answers after 7 years[J].Curr Opin Cardiol,2010,25(4):355-365.
[24]Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment［J］. Vasc Health Risk Manag, 2008, 4(1):23-30.
[25]Yamada S,Ano N,Toda K,et al.Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro[J].Hypertens Res,2008,31(4):601-606.
[26]Santilli F,Vazzana N,Liani R,et al.Platelet activation in obesity and metabolic syndrome[J].Obes Rev,2012,13(1):27-42.
[27]Vendrell J,El Bekay R,Peral B,et al.Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance[J].Endocrinology,2011,152(11):4072-4079.

备注/Memo

备注/Memo:
收稿日期：2013-11-12.
通讯作者：曹丰，主任医师，主要从事心肌再生机制及干预在体分子影像研究 Email：fengcao@fmmu.edu.cn
作者简介：江振华，硕士生 Email：jzhfmmu@163.com
更新日期/Last Update: 2014-06-05